According to the Complaint, Trevena, Inc. ("Trevena" or the Company) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates, including oliceridine (TRV130) to treat moderate to severe acute pain intravenously.

According to the Complaint, Cocrystal Pharma, Inc. ("Cocrystal" or the "Company", f/k/a/ BioZone Pharmaceuticals, Inc.) is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.

Plaintiff's law firm issued a press release on September 14, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint alleges that the Defendants made materially false and/or misleading statements and failed to disclose that: (1) OPKO and its Chairman and CEO, were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) the illicit scheme allowed the Company to report revenues from this illegal conduct and would result in governmental scrutiny including a complaint filed by the U.S. Securities and Exchange Commission; and (3) consequently, Defendants' statements about OPKO's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

According to the Complaint, Microchip Technology Incorporated ("Microchip" or the "Company") is a provider of microcontroller, mixed-signal analog and Flash-IP solutions.

According to the Complaint, USA Technologies provides wireless networking, cashless transactions, asset monitoring, and other value-added services in the United States and internationally.

Plaintiff's law firm issued a press release on August 27, 2018. According to the press release, CBS is a mass media company with operations in the entertainment, cable networks, publishing, and local media segments.

On August 24, 2018, Plaintiff’s law firm issued a press release announcing the law suit. According to the press release, on August 20, 2018, Citron Research published a report on twitter alleging that CV Sciences’ management misrepresented the status of one of its key patents. According to Citron Research, the Company failed to disclose a rejected patent that the Company “continue[d] to hype.” As a result of the Citron report, CV Sciences stock plunged over 63% in volatile trading.

On August 10, 2018, Plaintiff's law firm issued a press release announcing the filing of the Complaint. According to the press release, the Complaint alleges that, during the Class Period, Defendants violated provisions of the Exchange Act by issuing false and misleading press releases, filings with the U.S. Securities and Exchange Commission ("SEC"), and statements during investor and analyst conference calls.

Plaintiff's law firm issued a press release on August 8, 2018, announcing the law suit. According to the press release, the complaint charges Nielsen and certain of its officers with violations of the Securities Exchange Act of 1934. Nielsen describes itself as a leading global performance management company providing its clients with a comprehensive understanding of what consumers watch and what they buy and how those choices intersect.

According to the Complaint, Helios and Matheson Analytics Inc. ("Helios" or the "Company" identifies itself as a provider of information technology, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology.

According to the Complaint, Envision Healthcare Corporation ("Envision" or the "Company"), through its subsidiaries, provides various healthcare services in the United States. Envision operates through two segments, Physician Services and Ambulatory Services.

According to the Complaint, Glencore PLC (“Glencore” or the “Company”) engages in the production, refinement, processing, storage, transport and marketing of metals and minerals, energy products, and agricultural products worldwide. Glencore is incorporated in Jersey, United Kingdom, with headquarters in Baar, Switzerland. Glencore operates mines in the Democratic Republic of Congo (“DRC”).

According to the Complaint, Gogo Inc. ("Gogo" or the "Company"), through its subsidiaries, provides inflight broadband connectivity and wireless entertainment services to the aviation industry in the United States and
internationally.

According to the Complaint, the Company describes itself as "developing and commercializing a robotic device, the ARTAS System that assists physicians in performing many of the repetitive tasks that are a part of a follicular unit extraction surgery, a type of hair restoration procedure."

According to the Complaint, TAL Education Group ("TAL") provides educational services, and offers comprehensive tutoring services to students covering core academic subjects such as mathematics, English, Chinese, physics,
chemistry. The Company mainly serves students in China.

According to the Complaint, Ormat Technologies Inc. ("Ormat") engages in the geothermal and recovered energy power business worldwide.

Plaintiff's law firm issued a press release on June 8, 2018, announcing the lawsuit on behalf of purchasers of REV Group, Inc. (NYSE:REVG) securities pursuant and/or traceable to REV Group's initial public offering ("IPO") on or about January 27, 2017. The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) REV Group was unable to use its "strong visibility into future net sales" to "effectively plan" and manage its backlog of vehicles; (2) REV Group facilities were not operating efficiently or at a low cost to satisfy customer demand; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the Complaint, Aegean Marine Petroleum Network Inc. ("Aegean") is a marine fuel logistics company that markets and physically supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers. Aegean procures marine fuel from refineries, major oil producers, and other sources along with reselling and delivering these fuels from its bunkering vessels to end users.

According to the Complaint, Aegean Marine Petroleum Network Inc. ("Aegean") is a marine fuel logistics company that markets and physically supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers. Aegean procures marine fuel from refineries, major oil producers, and other sources along with reselling and delivering these fuels from its bunkering vessels to end users.

According to the law firm press release, Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers its products to the medical industry. The Company's lead product is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor ("IV meloxicam") to be used for the management of moderate to severe pain.